Placebo News and Research

RSS

10 million of us lack sunshine vitamin

Health pioneers BetterYou have welcomed the views of Nutritionist Marilyn Glenville, that ‘oil based supplements can help you get your recommended dose of vitamin D’.

From BetterYou Ltd 27 Jan 2016

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire plc today announced it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA on October 16, 2015.

25 Jan 2016

Chronic exposure to environmental toxin may up risk of neurodegenerative illness

A new study published today in the science journal Proceedings of the Royal Society B indicates that chronic exposure to an environmental toxin may increase risk of neurodegenerative illness. Conducted by scientists at the Institute for EthnoMedicine, a non-profit medical research organization, and the University of Miami Brain Endowment Bank, the study provides a foundation for future research in Alzheimer's disease, ALS and Parkinson's disease.

25 Jan 2016

Researchers use ASC secreted factors to create therapeutic factor concentrate for critical limb ischemia

"Critical limb ischemia" (CLI) describes an advanced stage of peripheral artery disease characterized by obstruction of the arteries and a markedly reduced blood flow to the extremities. CLI identifies patients at high-risk for major amputation. The estimated annual incidence of CLI ranges between 500 and 1000 new cases out of one million people per year, with the highest rates among the elderly, smokers, and those with diabetes. CLI is considered to be a critical public health issue. Attempts at revascularization are often unsuccessful.

22 Jan 2016

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan.

22 Jan 2016

Aged Garlic Extract beneficial for preventing heart disease

The supplement Aged Garlic Extract can reverse the buildup of deadly plaque in arteries and help prevent the progression of heart disease, according to a new study scheduled for publication in the Journal of Nutrition.

22 Jan 2016

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Allergan plc announced today the publication of the positive results of the Phase III trials of VIBERZITM C IV (eluxadoline) for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in the January 21 issue of The New England Journal of Medicine.

21 Jan 2016

Mood disorder experts question effectiveness of metyrapone drug

Pioneering research by mood disorder experts at Newcastle University has questioned the effectiveness of metyrapone, a drug suggested to treat depression.

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

Traditional acupuncture no better than fake acupuncture for treating menopause symptoms

A new study has revealed traditional Chinese acupuncture treatments are no better than fake acupuncture for treating menopause symptoms.

20 Jan 2016

Higher levels of Omega-3 fatty acids could boost B vitamins' effect in preventing cognitive decline

While research has already established that B vitamin supplements can help slow mental decline in older people with memory problems, an international team have now found that having higher levels of Omega-3 fatty acids in your body could boost the B vitamins' effect.

20 Jan 2016

Stem cell transplantation of neurotrophic factors shows promise in ALS

Mesenchymal stem cells cultured to secrete neurotrophic factors can be administered to patients with amyotrophic lateral sclerosis without lasting unwanted effects and may have clinical benefits, indicates a phase I/II safety analysis study.

19 Jan 2016

Selexipag reduces clinical events in PAH patients

Selexipag, alone or in combination with other classes of pulmonary arterial hypertension medication, reduced the composite rate of disease complications and deaths among patients in a phase III trial.

19 Jan 2016

TG4010 vaccine promising in advanced NSCLC

Addition of the TG4010 vaccine to first-line chemotherapy improves outcomes in patients with advanced non-small-cell lung cancer, show the results of a placebo controlled trial.

19 Jan 2016

Citalopram of limited use for dementia-associated agitation

The use of citalopram for the treatment of agitation in Alzheimer’s disease may be limited to a small group of people with moderate agitation and low levels of cognitive impairment, study findings suggest.

19 Jan 2016

Anticholinesterase offers a ‘steadying hand’ to PD patients

The dementia drug rivastigmine may reduce the risk of falls in patients with Parkinson’s disease by improving gait stability, findings from the phase II ReSponD trial show.

19 Jan 2016

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

Profectus BioSciences, Inc., a clinical-stage vaccine company developing novel vaccines for the prevention and treatment of infectious diseases and the treatment of cancer, announced today the initiation of a Phase 1 clinical study of Profectus' VesiculoVax-vectored Ebola virus vaccine.

19 Jan 2016

New sites opened across the South West for Alzheimer’s disease clinical trial

People with Alzheimer’s disease are helping with a ground-breaking government-funded trial but with new sites recently opened in the South West more people are being asked to take part in the study led by academics from the Universities of Bristol, Cambridge, Queen’s University Belfast and University College London, and hosted by North Bristol NHS Trust.

19 Jan 2016

Placebo News and Research

10 million of us lack sunshine vitamin

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Chronic exposure to environmental toxin may up risk of neurodegenerative illness

Researchers use ASC secreted factors to create therapeutic factor concentrate for critical limb ischemia

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Aged Garlic Extract beneficial for preventing heart disease

Allergan announces publication of VIBERZI Phase III trial results in The New England Journal of Medicine

Mood disorder experts question effectiveness of metyrapone drug

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

Traditional acupuncture no better than fake acupuncture for treating menopause symptoms

Higher levels of Omega-3 fatty acids could boost B vitamins' effect in preventing cognitive decline

Stem cell transplantation of neurotrophic factors shows promise in ALS

Selexipag reduces clinical events in PAH patients

TG4010 vaccine promising in advanced NSCLC

Citalopram of limited use for dementia-associated agitation

Anticholinesterase offers a ‘steadying hand’ to PD patients

Profectus begins Phase 1 clinical study of VesiculoVax-vectored Ebola virus vaccine

New sites opened across the South West for Alzheimer’s disease clinical trial

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News